Raban V Jeger1, Otmar Pfister1, Dragana Radovanovic2, Franz R Eberli3, Hans Rickli4, Philip Urban5, Giovanni Pedrazzini6, Jean-Christophe Stauffer7, Jörg Nossen8, Paul Erne9. 1. Department of Cardiology, University Hospital Basel, Basel, Switzerland. 2. AMIS Plus Data Centre, Epidemiology, Biostatistics, and Prevention Institute, University of Zurich, Zurich, Switzerland. 3. Department of Cardiology, Triemli Hospital, Zurich, Switzerland. 4. Department of Cardiology, St. Gallen Cantonal Hospital, St. Gallen, Switzerland. 5. Cardiovascular Department, La Tour Hospital, Geneva, Switzerland. 6. Department of Cardiology, Cardiocentro Ticino, Lugano, Switzerland. 7. Department of Cardiology, Fribourg Cantonal Hospital, Fribourg, Switzerland. 8. Department of Internal Medicine, Lucerne Cantonal Hospital, Sursee, Switzerland. 9. AMIS Plus, Zurich, Switzerland.
Abstract
BACKGROUND: Data on temporal trends of heart failure (HF) in acute coronary syndrome (ACS) are scarce. HYPOTHESIS: Improved treatment options may have led to lower case-fatality rates (CFRs) during the last years in ACS complicated by HF. METHODS: Patients of the nationwide Acute Myocardial Infarction in Switzerland (AMIS)-Plus ACS registry were analyzed from 2000 to 2014. RESULTS: Of 36 366 ACS patients, 3376 (9.3%) had acute or chronic HF, 2111 (5.8%) de novo acute HF (AHF), 964 (2.7%) chronic HF (CHF), and 301 (0.8%) acute decompensated CHF (ADCHF). In-hospital CFRs were highest in patients with ADCHF (32.6%) and de novo AHF (29.7%), followed by patients with CHF (12.9%) and without HF (3.2%, P < 0.001). Although in-hospital CFRs gradually decreased in CHF patients (14.3% to 4.5%, P = 0.003) and patients without HF (3.5% to 2.2%, P < 0.001), they remained high in patients with ADCHF (36.4% to 40.0%, P = 0.45) and de novo AHF (50.0% to 29.4%, P = 0.37). Although there was an increase in specific ACS therapies in the cohort over time, ACS patients with HF received significantly less pharmacological and interventional ACS therapies than patients without HF. There was no significant change in HF medication rates except less frequent use of β-blockers and diuretics in de novo AHF patients in recent years. CONCLUSIONS: HF is present in 1 out of 10 patients presenting with ACS and is associated with high in-hospital CFRs, particularly in acute HF. Although advances in ACS therapy improved in-hospital CFRs in patients with no HF or CHF, CFRs remained unchanged and high in patients with acute HF and ACS over the last decade.
BACKGROUND: Data on temporal trends of heart failure (HF) in acute coronary syndrome (ACS) are scarce. HYPOTHESIS: Improved treatment options may have led to lower case-fatality rates (CFRs) during the last years in ACS complicated by HF. METHODS:Patients of the nationwide Acute Myocardial Infarction in Switzerland (AMIS)-Plus ACS registry were analyzed from 2000 to 2014. RESULTS: Of 36 366 ACS patients, 3376 (9.3%) had acute or chronic HF, 2111 (5.8%) de novo acute HF (AHF), 964 (2.7%) chronic HF (CHF), and 301 (0.8%) acute decompensated CHF (ADCHF). In-hospital CFRs were highest in patients with ADCHF (32.6%) and de novo AHF (29.7%), followed by patients with CHF (12.9%) and without HF (3.2%, P < 0.001). Although in-hospital CFRs gradually decreased in CHFpatients (14.3% to 4.5%, P = 0.003) and patients without HF (3.5% to 2.2%, P < 0.001), they remained high in patients with ADCHF (36.4% to 40.0%, P = 0.45) and de novo AHF (50.0% to 29.4%, P = 0.37). Although there was an increase in specific ACS therapies in the cohort over time, ACS patients with HF received significantly less pharmacological and interventional ACS therapies than patients without HF. There was no significant change in HF medication rates except less frequent use of β-blockers and diuretics in de novo AHF patients in recent years. CONCLUSIONS: HF is present in 1 out of 10 patients presenting with ACS and is associated with high in-hospital CFRs, particularly in acute HF. Although advances in ACS therapy improved in-hospital CFRs in patients with no HF or CHF, CFRs remained unchanged and high in patients with acute HF and ACS over the last decade.
Authors: Judith S Hochman; Lynn A Sleeper; John G Webb; Vladimir Dzavik; Christopher E Buller; Philip Aylward; Jacques Col; Harvey D White Journal: JAMA Date: 2006-06-07 Impact factor: 56.272
Authors: Raban V Jeger; Shannon M Harkness; Krishnan Ramanathan; Christopher E Buller; Matthias E Pfisterer; Lynn A Sleeper; Judith S Hochman Journal: Eur Heart J Date: 2006-01-19 Impact factor: 29.983
Authors: Amit Segev; Bradley H Strauss; Mary Tan; Aurora A Mendelsohn; Kevin Lai; Thomas Ashton; David Fitchett; Etienne Grima; Anatoly Langer; Shaun G Goodman Journal: Am J Cardiol Date: 2006-06-19 Impact factor: 2.778
Authors: Michael S Cuffe; Robert M Califf; Kirkwood F Adams; Raymond Benza; Robert Bourge; Wilson S Colucci; Barry M Massie; Christopher M O'Connor; Ileana Pina; Rebecca Quigg; Marc A Silver; Mihai Gheorghiade Journal: JAMA Date: 2002-03-27 Impact factor: 56.272
Authors: Matthew T Roe; Anita Y Chen; Arthur L Riba; Raj Gopal Goswami; W Frank Peacock; Charles V Pollack; Sean P Collins; W Brian Gibler; E Magnus Ohman; Eric D Peterson Journal: Am J Cardiol Date: 2006-04-21 Impact factor: 2.778
Authors: Markku S Nieminen; Dirk Brutsaert; Kenneth Dickstein; Helmut Drexler; Ferenc Follath; Veli-Pekka Harjola; Matthias Hochadel; Michel Komajda; Johan Lassus; Jose Luis Lopez-Sendon; Piotr Ponikowski; Luigi Tavazzi Journal: Eur Heart J Date: 2006-09-25 Impact factor: 29.983
Authors: Alexandre Mebazaa; Markku S Nieminen; Milton Packer; Alain Cohen-Solal; Franz X Kleber; Stuart J Pocock; Roopal Thakkar; Robert J Padley; Pentti Põder; Matti Kivikko Journal: JAMA Date: 2007-05-02 Impact factor: 56.272
Authors: Philippe Gabriel Steg; Omar H Dabbous; Laurent J Feldman; Alain Cohen-Solal; Marie-Claude Aumont; José López-Sendón; Andrzej Budaj; Robert J Goldberg; Werner Klein; Frederick A Anderson Journal: Circulation Date: 2004-01-26 Impact factor: 29.690
Authors: Katherine M Breen; Lorna Finnegan; Karen M Vuckovic; Anne M Fink; Wayne Rosamond; Holli A DeVon Journal: Heart Lung Date: 2021-06-05 Impact factor: 3.149